Immunovia (IMMNOV) Q4 2024 earnings summary

Executive summary

• Completed development and clinical validation of a next-generation pancreatic cancer test, demonstrating significant improvements in sensitivity and specificity over previous standards and current imaging methods.

• The CLARITI study, the largest of its kind, showed sensitivity of 78% and specificity of 94%, outperforming CA19-9 and imaging modalities.

• Transitioned from R&D to commercialization, with a targeted US launch in Q3/Q4 2025, focusing on high-risk surveillance centers and pursuing reimbursement and regulatory approvals.

• Strategic partnership discussions are ongoing to support broader commercialization and regulatory expertise.

• Demonstrated superior test performance in recent blood samples, indicating strong real-world applicability.

Financial highlights

• Q4 2024 operating expenses were 30.6 MSEK, up 7.0 MSEK year-over-year, with declining headcount and rising clinical study costs.

• Q4 2024 cash burn averaged just over 9 MSEK per month, totaling 28.3 MSEK, in line with guidance.

• Rights issue in autumn 2024 raised 53 MSEK net, with 91% subscription; TO2 warrants exercised in January 2025 brought in 37 MSEK (74.1% participation).

• End-Q4 cash balance was 25.3 MSEK, with additional proceeds from warrants expected to fund operations into H2 2025.

• Q4 profitability was due to unrealized FX gains from intercompany loans, not operational profit.

Outlook and guidance

• Commercial launch of the next-generation test in the US planned for Q3/Q4 2025, initially via a focused, cost-effective approach targeting high-risk centers.

• Monthly cash burn for 2025 expected at 8–10 MSEK, with OpEx shifting from R&D to clinical studies and commercialization.

• Additional clinical studies planned in 2025 to support reimbursement, physician adoption, and regulatory submissions.

• Management expects current funding to cover operational needs into the second half of 2025, with further liquidity options being explored.

• Anticipates major milestones in 2025, including results from a second clinical validation study and progress toward reimbursement.